Maia wrote:LMighty, so happy to hear! An actual step in the right direction!
Is your mom feeling more comfortable now? Not needing the drainage is itself such a relief.
LMighty wrote:Update #2: It has been 2 weeks since the start of the new regimen. Today's X-ray showed slight decrease of shadowy area in both lungs. Our onc said it's a very positive and miraculous response considering we are only 2 weeks in!
I may post another update after further scans tomorrow.
sdino wrote: Maia Is this for only Kras Wild type ? My wife is Kras Mutant. .
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Johanna C. Bendell, Tae Won Kim, Boon C. Goh, Jeffrey Wallin, Do-Youn Oh, Sae-Won Han, Carrie B. Lee, Matthew David Hellmann, Jayesh Desai, Jeremy Howard Lewin, Benjamin J. Solomon, Laura Quan Man Chow, Wilson H. Miller, Justin F. Gainor, Keith Flaherty, Jeffrey R. Infante, Meghna Das-Thakur, Paul Foster, Edward Cha, and Yung-Jue Bang
Journal of Clinical Oncology 2016 34:15_suppl, 3502-3502
Results: As of October 12, 2015, 23 CRC (22 KRAS mutant, 1 WT) pts were enrolled during escalation and expansion. No dose-limiting toxicities were observed, and expansion occurred at atezo 800 mg q2w and cobi 60 mg. Median follow-up for safety in CRC pts was 3.78 mo (range, 1.1-11.7). The most common treatment-related AEs included diarrhea (69.6%), fatigue (52.2%), dermatitis acneiform (43.5%), rash (34.8%), maculopapular rash (26.1%), pruritus (26.1%) and nausea (26.1%). Incidence of treatment-related G3-4 AEs was 34.8%. The only treatment-related G3-4 AE in ≥ 2 pts was diarrhea (8.7%). No G5 AEs were reported. The ORR was 17% (4 PR, 5 SD). Three responses were ongoing (range, 4.0 to 7.7 mo at time of data cutoff). Three responders were mismatch repair-proficient [that means: MSS], and 1 was unknown. Response was not associated with baseline PD-L1 expression. Results from the serial biopsy cohort showed enhanced PD-L1 upregulation, CD8 T-cell infiltration and MHC I expression on treatment, providing mechanistic rationale for the combination.
Conclusions: The combination of cobi and atezo in CRC is well tolerated at the maximum administered doses. These results show that pts with MSS CRC can respond to the combination of cobi and atezo, and provide support for continued evaluation of the combination. Clinical trial information: NCT01988896.
http://ascopubs.org/doi/abs/10.1200/JCO ... suppl.3502
Users browsing this forum: No registered users and 33 guests